沙库巴曲缬沙坦在心血管疾病中应用研究进展

Research Progress of Sacubitri/valsartan in Cardiovadcular Disease

近年来,多项研究表明沙库巴曲缬沙坦治疗射血分数降低的心力衰竭(HFrEF)效果优于传统药物血管紧张素转换酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)。2019年欧洲心脏病学会专家共识会议报告指出,沙库巴曲缬沙坦可作为新发HFrEF或失代偿性心力衰竭〔左心室射血分数(LVEF)<40%〕住院或门诊患者的起始治疗方案。本文综述沙库巴曲缬沙坦在多种心血管疾病如HFrEF、射血分数中间值的心力衰竭、射血分数保留的心力衰竭、急性失代偿性心力衰竭、急性心肌梗死、高血压、慢性肾脏病、糖尿病、儿童心力衰竭中的研究进展,并分析其安全性和不良反应,同时指出未来研究方向。

In recent years,several important studies in the field of heart failure with reduced ejection fraction(HFrEF)have shown that sacubitril/valsartan is superior to traditional drugs angiotensin-converting enzyme inhibitors(ACEI)/angiotensinⅡblockers(ARB).An expert consensus meeting report of the heart failure association of the european society of cardiology reports that initiation of sacubitril/valsartan may be considered for patients hospitalized with new-onset heart failure or decompensated chronic heart failure(LVEF<40%).This article reviewed the additional cardiovascular protective effects of sacubitril/valsartan,such as HFrEF,heart failure with mid-range ejection fraction,heart failure with preserved ejection fraction,acute decompensated heart failure,heart failure after acute myocardial infarction,hypertension,chronic kidney disease,diabetes,and paediatric heart failure.We will analyze their safety,adverse reactions,and point out future research directions.